SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the safety and efficacy of RF ablation using the Intracept Intraosseous Nerve Ablation System to ablate intraosseous nerves for the relief of chronic axial low back pain. This is a prospective, double-blind, randomized, sham-controlled clinical trial with an optional crossover component.
| Condition | Intervention |
|---|---|
|
Low Back Pain |
Device: Intracept Treatment |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Prospective Randomized, Double-blind, Controlled Investigation Evaluating the Intracept Intraosseous Nerve Ablation System for the Reduction of Pain in Patients With Chronic Axial Low Back Pain |
- Oswestry Disability Index [ Time Frame: 3 months ] [ Designated as safety issue: No ]The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain.
- Patient Success at 3 months and Oswestry Disability Index at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 200 |
| Study Start Date: | October 2011 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Intracept Treatment |
Device: Intracept Treatment
Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
|
| Sham Comparator: Sham Treatment |
Device: Intracept Treatment
Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
|
Eligibility| Ages Eligible for Study: | 25 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Skeletally mature patients age 25 - 70 years, inclusive
- Chronic lower back pain for at least six (6) months
Failure to respond to at least six (6) months of non-operative conservative management. The minimum requirment is as follows:
- Analgesic therapy (minimum of 2 weeks) and a minimum of 4 weeks of NSAID therapy
- Supervised exercise program(minimum of 12 sessions)
- Oswestry Disability Index (ODI) at time of evaluation of at least 30 points
- Baseline Visual Analog Scale (VAS) of at least 4cm on a 10cm scale
The following test indicating that the vertebral body is the source of pain:
1.MRI showing Type 1 or Type II Modic changes at least one vertebral endplate, at one or more levels from L3 to S1
- Understands the local language and is willing and able to follow the requirements of the protocol
- Understands the informed consent and signs the institutional review board/ independent ethics committee (IRB/IEC) approved informed consent form
Exclusion Criteria:
- Radicular pain by history or evidence of pain or neurological deficit in a dermatonal zone at or below the medial thigh.
- Previous surgery performed on the lumbar spine
- History of symptomatic spinal stenosis
- History of osteoporotic or tumor-related vertebral body compression fracture
- History of vertebral cancer or spinal metastasis
- History of spinal infection
- Metabolic bone disease (e.g. osteogenesis imperfecta)
- BMI ≥40
- Osteoporosis, defined as T score <-2.5
Any radiographic evidence of other important back pathology, such as:
- Nerve root compression or severe effacement of the thecal sac that correlates with radicular pain or muscle weakness
- Disc extrusion or disc protrusion >5mm
- Facet arthrosis or facet effusion at any lumbar level that correlates with clinical evidence of facet mediated low back pain
- Spondylolisthesis 2mm or greater at any level
- Spondylolysis at any level
- MRI evidence of Modic changes, Type I or Type II at greater than 3 vertebral bodies.
- Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain
- Demonstrates 3 or more Waddell's signs of Inorganic Behavior
- Any evidence of current systemic infection
- Uncorrected bleeding diathesis
- Any neurologic problem that prevents early mobilization after surgery or interferes with assessment of ODI
- Contraindication to MRI or patients who have allergies to the components of the Intracept device
- Pregnant, lactating or plan to become pregnant in next year
- Diabetes requiring daily insulin
- Current use of steroid therapy, with the exception of inhalation steroids for asthma
- Evidence of mental instability or uncontrolled depression; patients requiring anti-depressants or anti-psychotics within 3 months of enrollment are not eligible; patients with a Beck Depression Score of greater than 24 are not eligible
- Receiving Workmen's Compensation
- Currently involved in litigation regarding back pain/injury or financial incentive to remain impaired
- Any medical condition that impairs follow-up
- Contraindications to the proposed anesthetic protocol.
- Evidence of substance abuse; patients using prescribed extended release narcotics are not eligible (e.g. fentanyl patch,MS contin, oxycontin)
- Known to require at the time of screening and/or randomization, additional surgery to the lumbar spinal region within six months
- Being treated with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed)
- Has a life expectancy of less than 1 year
- Has active implantable devices, such as cardiac pacemakers, spinal cord stimulators, etc.
- Is a prisoner
Contacts and Locations| United States, Arizona | |
| Desert Institute for Spine Care | Recruiting |
| Phoenix, Arizona, United States, 85020 | |
| Contact: Jennifer Camoriano 480-695-0681 jennifer@jehnresearch.com | |
| Principal Investigator: Christopher Yeung, MD | |
| Sub-Investigator: Anthony Yeung, MD | |
| Sub-Investigator: Justin Field, MD | |
| United States, California | |
| Memorial Orthopedic Surgical Group | Recruiting |
| Long Beach, California, United States, 90806 | |
| Contact: Nanette Chavez 888-978-8396 nanettechavez@gmail.com | |
| Principal Investigator: Phil Yuan, MD | |
| Sub-Investigator: Curtis Spencer, MD | |
| Sub-Investigator: Kasra Rowshan, MD | |
| The Spine Institute | Recruiting |
| Santa Monica, California, United States, 90403 | |
| Contact: Annie Sharabidze 888-978-8396 Annie.Sharabidze@cshs.org | |
| Principal Investigator: Hyun Bae, MD | |
| Sub-Investigator: Timothy Davis, MD | |
| United States, Georgia | |
| Pain Center Solutions | Recruiting |
| Marietta, Georgia, United States, 30060 | |
| Contact: Austin Filitor 888-978-8396 afilitor@drugstudies.net | |
| Principal Investigator: Michael Schaufele, MD | |
| Sub-Investigator: Marvin Tark, MD | |
| United States, Indiana | |
| Indiana Spine Group | Recruiting |
| Carmel, Indiana, United States, 46032 | |
| Contact: Sheetal Vinayek 317-715-5897 svinayek@indianaspinegroup.com | |
| Principal Investigator: Rick Sasso, MD | |
| Sub-Investigator: Kevin Macadaeg, MD | |
| United States, Maine | |
| Maine Medical Partners | Recruiting |
| Scarborough, Maine, United States, 04074 | |
| Contact: Deborah Cushing 888-978-8396 cushid@mmc.org | |
| Principal Investigator: Lee Thibodeau, MD | |
| Sub-Investigator: Douglas Buxton, MD | |
| United States, Michigan | |
| Partners in Research and Educational Studies of Spinal Disorders (PressD) | Recruiting |
| Southfield, Michigan, United States, 48033 | |
| Contact: Claudia Westbrook, RN 888-978-8396 smartstudycjw@gmail.com | |
| Principal Investigator: Lawrence T Kurz, MD | |
| Sub-Investigator: Michael Sikorsky, MD | |
| Sub-Investigator: Dan Park, MD | |
| United States, North Carolina | |
| OrthoCarolina | Recruiting |
| Charlotte, North Carolina, United States, 28207 | |
| Contact: Caryn Thompson 704-323-2778 caryn.thompson@orthocarolina.com | |
| Contact: Rebekah Smith 704-323-2278 rebekah.smith@orthocarolina.com | |
| Principal Investigator: Alfred Rhyne, MD | |
| Sub-Investigator: Sarjoo Bhagia, MD | |
| United States, Oregon | |
| NeuroSpine Institute | Recruiting |
| Eugene, Oregon, United States, 97401 | |
| Contact: Shawn Potts 541-393-0100 spotts@neurospinellc.com | |
| Principal Investigator: Scott Kitchel, MD | |
| Sub-Investigator: Greg Moore, MD | |
| United States, Pennsylvania | |
| Rothman Institute | Recruiting |
| Philadelphia, Pennsylvania, United States, 19107 | |
| Contact: AnneMarie Madden 888-978-8396 annemarie.madden@rothmaninstitute.com | |
| Contact: Victor Popov 888-978-8396 victor.popov@rothmaninstitute.com | |
| Principal Investigator: D. Greg Anderson, MD | |
| Sub-Investigator: Kristen Radcliff, MD | |
| Principal Investigator: | Jeffrey Fischgrund, MD | Michigan Orthopaedic Institute |
More Information
No publications provided
| Responsible Party: | Relievant Medsystems, Inc. |
| ClinicalTrials.gov Identifier: | NCT01446419 History of Changes |
| Other Study ID Numbers: | CIP 0003 |
| Study First Received: | October 3, 2011 |
| Last Updated: | September 11, 2012 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by Relievant Medsystems, Inc.:
|
chronic axial low back pain vertebrogenic pain Radio frequency ablation |
Additional relevant MeSH terms:
|
Back Pain Low Back Pain Pain |
Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on May 19, 2013